Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is New Ray Medicine International Holding PB Ratio?
New Ray Medicine International HoldingHKSE:06108 52 PB Ratio is 0.11 as of Aug. 26, 2026, which is 76% below its 10-year median of 0.45. GuruFocus rates HKSE:06108 with a GF Score™ of 52/100 and a GF Value™ of HK$1.04 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 612 Healthcare Providers & Services companies, New Ray Medicine International Holding ranks better than 99.02% on this metric.
HKSE:06108's PB Ratio is ranked better than 99.02% of 612
companies
in the Healthcare Providers & Services industry
Industry Median: 1.98
vs HKSE:06108: 0.11
During the past 12 months, New Ray Medicine International Holding's average Book Value Per Share Growth Rate was -24.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -10.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -14.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of New Ray Medicine International Holding was 25.30% per year. The lowest was -34.30% per year. And the median was -7.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
New Ray Medicine International Holding PB Ratio Related Terms
New Ray Medicine International Holding PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding PB Ratio Chart
New Ray Medicine International Holding Annual Data
New Ray Medicine International Holding PB Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's PB Ratio distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's PB Ratio falls into.
New Ray Medicine International Holding PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
New Ray Medicine International Holding (HKSE:06108) has a PB Ratio of 0.11 as of Aug. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on New Ray Medicine International Holding and its competitors. This is 76% below median its historical median of 0.45. Over the past decade, New Ray Medicine International Holding's PB Ratio has ranged from 0.09 to 6.08. According to the industry distribution chart, New Ray Medicine International Holding ranks #6 out of 612 companies in the Healthcare Providers & Services industry, placing it in the top 1%.
Is New Ray Medicine International Holding's PB Ratio too high?
New Ray Medicine International Holding's current PB Ratio of 0.11 is 76% below median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 6.08. The Healthcare Providers & Services industry median PB Ratio is 1.98. New Ray Medicine International Holding's value of 0.11 is 94.4% below this industry median. Based on the distribution chart, New Ray Medicine International Holding ranks #6 out of 612 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, New Ray Medicine International Holding has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does New Ray Medicine International Holding's PB Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, New Ray Medicine International Holding ranks #6 out of 612 companies for PB Ratio. This places New Ray Medicine International Holding in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.98. New Ray Medicine International Holding's value of 0.11 is 94.4% below this benchmark. Historically, New Ray Medicine International Holding's own PB Ratio has ranged from 0.09 to 6.08 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 1.98, New Ray Medicine International Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.98, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Ray Medicine International Holding's current PB Ratio of 0.11 is 94.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on New Ray Medicine International Holding and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Ray Medicine International Holding's current PB Ratio is 0.11, which is 76% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Ray Medicine International Holding stock overvalued right now?
Based on GuruFocus' analysis, New Ray Medicine International Holding (HKSE:06108) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.04, compared to a current price of HK$0.23 — trading 78.4% below its estimated fair value. The current PB Ratio is 0.11, which is 76% below median its 10-year median of 0.45 and 94.4% below the Healthcare Providers & Services industry median of 1.98. New Ray Medicine International Holding's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For New Ray Medicine International Holding (HKSE:06108), the current PB Ratio is 0.11 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?
Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued.
The current stock price of HK$0.23 is trading 78.4% below its estimated GF Value™ of HK$1.04.
GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.
Key valuation signals for HKSE:06108:
PB Ratio: 0.11 (76% below median its 10-year median of 0.45)
GF Value™: HK$1.04 vs. price of HK$0.23 (78.4% below fair value)
Industry Position: 94.4% below the Healthcare Providers & Services median (#6 of 612)
No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
52GF Score
Get the complete analysis for HKSE:06108
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06108 has been successfully added to your 
